Mr. Hani Zabaneh reports

ADAPTOGENICS HEALTH CORP. ANNOUNCES STRATEGIC REVIEW OF HEALTH & WELLNESS OPPORTUNITIES AND MANAGEMENT CHANGES

Adaptogenics Health Corp. has initiated a strategic review to evaluate potential business opportunities within the broader health and wellness sector.

As part of this review, the company's board of directors and senior management are examining a range of potential strategic initiatives, which may include prospective business line transitions, strategic partnerships, acquisitions, divestitures, capital markets activities or other strategic actions designed to evaluate opportunities to support the company's long-term strategy and positioning within evolving health and wellness markets.

The purpose of the strategic review is to assess whether alignment with emerging trends, technologies and consumer demand in the health, nutrition and wellness space may support the company's long-term strategic objectives. The company is also evaluating whether the repositioning, expansion or development of new product platforms or distribution strategies is feasible and commercially viable in both the Canadian marketplace and selected international markets.

No decision has been made to pursue any transaction, restructuring, business transition or other strategic initiative at this time. There can be no assurance that the strategic review will result in any specific outcome, recommendation or change to the company's current operations. The company has not established a timetable for completion of the review and does not intend to comment further unless required under applicable Canadian securities laws, including National Instrument 51-102 -- Continuous Disclosure Obligations, National Policy 51-201 -- Disclosure Standards or the policies of the Canadian Securities Exchange.

Management changes

The company also announces the appointment of Anthony Franco as a director and chief executive officer of the company.

Mr. Franco is a seasoned operations and strategy executive with over 20 years of experience across the legal, technical and biotech industries. He holds a bachelor's degree in business management from Southern Connecticut State University and a juris doctorate from Western New England School of Law. He has an established record helping organizations define their ways of working, develop their strategy and achieve their corporate goals. Most recently, he served as the general manager of ReST Therapeutics, a neuropsychiatric start-up developing therapies for PTSD, Alzheimer's and traumatic brain injury. Mr. Franco was also the chief operating officer for Infinant Health, where he was responsible for operational changes within their consumer supplement division and establishing the pharmaceutical development program focusing on rare pediatric diseases. For the decade prior, he held numerous positions of increasing leadership at Alexion Pharmaceuticals in product development, global operations, corporate real estate and information technology until its acquisition by AstraZeneca. Early in his career, he also managed a successful legal practice focused on corporate real estate and business law.

Mr. Franco will spearhead the company's strategic review of health and wellness opportunities.

Mr. Franco replaces Daryl Ware-Lane, who has resigned as director, president and chief executive officer of the company. The company thanks Mr. Ware-Lane for his services as a director and chief executive officer of the company and wishes him all the best in his future endeavours.

About Adaptogenics Health Corp.

Adaptogenics Health is a Canadian-based nutraceutical company that has focused on the formulation and distribution of functional mushroom products and nutritional supplement alternatives. The company is committed to its mission of improving and empowering human health and well-being.

We seek Safe Harbor.